COLUMBIA, S.C. (August 24, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, launched a new sterile unit dose generic product, Cromolyn Sodium Inhalation Solution, USP (20 mg/2 ml). The single-dose vial product joins a range of other inhalation solutions produced by Ritedose Pharmaceuticals and is available in cartons
Ritedose Launches <em>Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL)</em> to Meet National Drug Shortage
COLUMBIA, S.C. (May 9, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose vial product, Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL). It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose
COLUMBIA, S.C. (April 25, 2023) – The Ritedose Corporation (Ritedose), an industry leader in pharmaceutical development, aseptic cGMP manufacturing and 503B outsourcing solutions, has begun production of a particular form of Albuterol Sulfate that the FDA has listed in short supply in the United States. It will be available in May.
Ritedose Pharmaceuticals Launches New Product: <em>Arformoterol Tartrate Inhalation Solution (15 mcg/2 ml)</em>
COLUMBIA, S.C. (April 13, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose oral inhalation product, Arformoterol Tartrate (15 mcg/2 ml), making the company the largest generic drug maker of its kind. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a
COLUMBIA, S.C. (January 30, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, has been awarded a group purchasing agreement with Premier Inc., a leading healthcare improvement company operating one of the nation’s largest group purchasing organizations (GPOs). Effective January 1, 2023, the new agreement allows Premier members,